<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000300009</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2022000300009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Incidencia de hipopotasemia en pacientes con neutropenia febril que reciben tratamiento con anfotericina B liposomal]]></article-title>
<article-title xml:lang="en"><![CDATA[Incidence of hypokalemia in patients with febrile neutropenia receiving treatment with liposomal amphotericin B]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cantarelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nazco-Casariego]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Complejo Hospitalario Universitario de Canarias Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Tenerife ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>263</fpage>
<lpage>266</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000300009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivos: Describir la incidencia, la gravedad y los factores asociados a la aparición de hipopotasemia en pacientes con neutropenia febril en tratamiento con anfotericina B liposomal.  Métodos: Estudio unicéntrico retrospectivo (enero 2010mayo 2020), que incluyó a aquellos pacientes hematológicos con neutropenia febril que recibieron tratamiento con anfotericina B liposomal durante al menos 72 h. Se evaluó la incidencia de aparición de hipokalemia asociada al empleo del fármaco, la gravedad de la misma, así como el impacto del empleo de una suplementación de potasio sobre la aparición de hipokalemia en este grupo de pacientes.  Resultados: Se incluyeron 89 pacientes (50,6% mujeres [n=45]; edad media 63,5 años [20-90]). El 59,6% (n=53) de los pacientes desarrolló hipopotasemia durante el tratamiento con anfotericina B liposomal: leve (52,8%, n=28), moderada (35,8%, n=19) y grave (11,3%, n=6). El empleo de una suplementación de inicio precoz a base de potasio disminuyó la tasa de aparición de hipokalemia en estos pacientes (p=0,001). El periodo entre el inicio del fármaco y el aporte de potasio fue menor en pacientes que no desarrollaron hipokalemia (p&lt;0,001). Asimismo, este grupo de pacientes se benefició de periodos más prolongados de suplementación (p=0,002) y terapia antifúngica (p=0,039).  Conclusiones: La hipopotasemia es un efecto adverso muy frecuente en pacientes con neutropenia febril que reciben tratamiento con anfotericina B liposomal, siendo necesario el establecimiento de protocolos de suplementación de potasio que disminuyan el riesgo de aparición de esta reacción adversa.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objectives: To describe the incidence, severity and factors associated with the appearance of hypokalemia in patients with febrile neutropenia in treatment with liposomal amphotericin B.  Methods: Retrospective unicenter study (January 2010-May 2020), which included those hematological patients with febrile neutropenia who were treated with liposomal amphotericin B for at least 72 h. The incidence of hypokalemia associated with the use of the drug, itsseverity, and the influence of potassiumsupplementation on the occurrence ofhypokalemia in this group of patientswere evaluated.  Results: 89 patients were included (50.6% women [n=45]; mean age 63.5 years [20-90]). 59.6% (n=53) of patients developed hypokalemia during treatment with liposomal amphotericin B: mild (52.8%, n=28), moderate (35.8%, n=19) and severe (11.3%, n=6). The use of early-onset potassium-based supplementation decreased the rate of occurrence of hypokalemia in these patients (p=0.001). The period between drug initiation and potassium intake was lower in patients who did not develop hypokalemia (p&lt;0.001). Likewise, this group of patients benefited from longer periods of supplementation (p=0.002) and antifungal therapy (p=0.039).  Conclusions: Hypokalemia is a very frequent adverse effect in patients with febrile neutropenia who are treated with liposomal amphotericin B. It is necessary to establish protocols for potassium supplementation to reduce the risk of this adverse reaction.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipokalemia]]></kwd>
<kwd lng="es"><![CDATA[neutropenia febril]]></kwd>
<kwd lng="es"><![CDATA[anfotericina B liposomal]]></kwd>
<kwd lng="es"><![CDATA[agentes antifúngicos]]></kwd>
<kwd lng="es"><![CDATA[efectos adversos]]></kwd>
<kwd lng="en"><![CDATA[Hypokalemia]]></kwd>
<kwd lng="en"><![CDATA[febrile neutropenia]]></kwd>
<kwd lng="en"><![CDATA[liposomal amphotericin B]]></kwd>
<kwd lng="en"><![CDATA[antifungal agents]]></kwd>
<kwd lng="en"><![CDATA[adverse effects]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhardwaj]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Navada]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of chemotherapy-induced neutropenic fever]]></article-title>
<source><![CDATA[Hosp Pract]]></source>
<year>2013</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-108</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nordvig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aagaard]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Daugaard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sengeløv]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lundgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Febrile Neutropenia and Long-term Risk of Infection among Patients Treated with Chemotherapy for Malignant Diseases]]></article-title>
<source><![CDATA[Open Forum Infect Dis]]></source>
<year>2018</year>
<volume>5</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shibuya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical management of pulmonary aspergillosis]]></article-title>
<source><![CDATA[JapanMed Assoc J]]></source>
<year>2005</year>
<volume>48</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>601-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gudiol]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Guisado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Azanza]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Candel]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cantón]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carratalà]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2020</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>174-81</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bresnik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ebrahimi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: A pooled analysis]]></article-title>
<source><![CDATA[Mycoses]]></source>
<year>2007</year>
<volume>50</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Azuma]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Imanishi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zamami]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kirino]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2018</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>252-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usam]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kimura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kanematsu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakashima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2014</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>941-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
